• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Aurobindo Pharma Ltd.
    27 May 2025
    USFDA Observation
    1040.30
    0.52%
    Aurobindo Pharma Share Price Rises After Q4 Revenue Growth
    Aurobindo Pharma Share Price Rises After Q4 Revenue Growth
    NDTV Profit
    Aurobindo Pharma reported a consolidated revenue increase of 10.6% year-on-year, reaching Rs 8,382 crore in Q4 FY25.
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. has lost -32.86% in the last 1 Year
    Aurobindo Pharma Q4 results: Profit dips to 903 cr, revenue up 11%
    Business Standard | 26 May 2025 5 more
    Aurobindo Pharma Q4 net dips 0.5%, revenue up 10.5% to Rs 8,382 cr
    Business Standard | 26 May 2025
    Aurobindo Pharma's Q4 net down marginally to 903 crore
    Business Line | 26 May 2025
    Aurobindo Pharma Q4 PAT falls marginally to 903 cr, revenue up 10%
    Business Standard | 26 May 2025
    Aurobindo Pharma Q4 result: PAT falls marginally to 903 cr, revenue up 10%
    Business Standard | 26 May 2025
    Aurobindo Pharma Q4 Results: Profit Stays Flat, Misses Estimates
    NDTV Profit | 26 May 2025
    logo
    Lupin Ltd.
    26 May 2025
    1935.80
    -0.78%
    Lupin signs licensing deal with SteinCares for ranibizumab in LatAm
    Business Standard
    Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. has an average target of 2326.00 from 8 brokers.
    Lupin inks licence agreement to commercialise biosimilar in Latin America
    Business Line | 26 May 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    26 May 2025
    Product Launch
    1995.00
    -0.47%
    Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates
    Glenmark Pharma Share Price Slumps After Q4 Results Miss Estimates
    NDTV Profit
    Glenmark Pharma reported a 6.3% increase in consolidated revenue, reaching Rs 3,256 crore compared to Rs 3,063 crore in the same quarter last year.
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd.'s price crossed below 50Day SMA today
    logo
    Dr. Reddy's Laboratories Ltd.
    25 May 2025
    1265.70
    0.28%
    Dr Reddy's gets 2 observations from USFDA for Telangana API plant
    Business Line
    USFDA completed a GMP inspection at the company's API manufacturing facility (CTO-5) in Miryalaguda, Telangana, the Hyderabad-based drug maker said in late evening filing on Saturday
    Copy LinkShare onShare on Share on Share on
    Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.
    logo
    Cipla Ltd.
    24 May 2025
    1575.50
    -0.18%
    Glenmark Consumer Care incorporated as a wholly-owned subsidiary
    Business Line
    Several drugmakers, domestic and multinational, have adopted similar strategies, including Cipla, and Sanofi, to name a few
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.
    logo
    Sun Pharmaceutical Industries Ltd.
    24 May 2025
    1564.00
    -0.93%
    Sun Pharma to invest $25 million in US biopharmaceutical company Pharmazz Inc
    Business Line
    Sun Pharma said the investment would give it the option to negotiate licensing of Sovateltide for marketing and distribution in certain developed market countries
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    Sun Pharma Targets Mid-To-High Single-Digit Growth In FY26
    NDTV Profit | 24 May 2025 1 more
    Sun Pharma to invest $25 million in Pharmazz Inc; raises stake to 22.7%
    Business Standard | 23 May 2025
    V
    Venus Remedies Ltd.
    24 May 2025
    470.00
    0.40%
    Venus Remedies gets GMP renewal certification from Ukraine's SMDC
    Business Standard
    Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 .
    Copy LinkShare onShare on Share on Share on
    Venus Remedies Ltd. has gained 37.95% in the last 1 Year
    logo
    Glenmark Pharmaceuticals Ltd.
    23 May 2025
    Product Launch
    1995.00
    -0.47%
    Glenmark Pharmaceuticals Q4 Results: Company Swings To Profit
    Glenmark Pharmaceuticals Q4 Results: Company Swings To Profit
    NDTV Profit
    The company declared a dividend of Rs 2.5 apiece with a face value of Rs 2 each for fiscal 2025.
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuti.. has an average target of 1997.50 from 5 brokers.
    logo
    Sun Pharmaceutical Industries Ltd.
    23 May 2025
    1564.00
    -0.93%
    Weak guidance, higher costs to weigh on Sun Pharma's FY26 outlook
    Business Standard
    Sun Pharma's FY26 revenue guidance disappoints Street expectations as higher specialty product costs in the US prompt brokerages to cut earnings estimates
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    Sun Pharma To Increase Stake In US-Based Stroke Drug Maker For $25 Million
    NDTV Profit | 23 May 2025 9 more
    Sun Pharma Q4 Review: Strong Domestic Growth Offset By Weakness In US Generics; Systematix Maintains 'Buy'
    NDTV Profit | 23 May 2025
    Sun Pharma shares down 5% post Q4 results, brokerages divided
    Business Line | 23 May 2025
    Sun Pharma share price slips 5% after Q4 results; check key numbers here
    Business Standard | 23 May 2025
    Sun Pharma Share Price Falls Nearly 5% After Q4 Profit Misses Estimates
    NDTV Profit | 23 May 2025
    Sun Pharma Q4 Review: Brokerages Stay Bullish Despite Soft FY26 Guidance
    NDTV Profit | 23 May 2025
    Sun Pharma Q4 results: Profit down 19% at Rs 2,149.8 cr, revenue up 8%
    Business Standard | 22 May 2025
    Sun Pharma Board Declares Dividend Of Rs 5.5 Per Share Check Record Date
    NDTV Profit | 22 May 2025
    Sun Pharmaceuticals Q4 Results: Profit Falls 19%, Misses Estimates
    NDTV Profit | 22 May 2025
    Sun Pharma Q4 results: Net profit falls 19% to 2,153.9 cr, revenue up 8%
    Business Standard | 22 May 2025
    logo
    Alembic Pharmaceuticals Ltd.
    23 May 2025
    Insider Trades
    959.95
    0.44%
    Alembic Pharma receives USFDA approval for generic hypertension drug
    Business Standard
    Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of amlodipine and atorvastatin tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement. These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added. Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd